IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0651289
(2012-10-12)
|
등록번호 |
US-9738727
(2017-08-22)
|
발명자
/ 주소 |
- Wu, Yan
- van Lookeren-Campagne, Menno
- Kirchhofer, Daniel
- Lipari, Michael Terry
- Katschke, Jr., Kenneth J.
- Moran, Paul M.
- Stawicki, Scott
- Liang, Wei-Ching
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
111 |
초록
The invention provides anti-HtrA1 antibodies and methods of using the same.
대표청구항
▼
1. An isolated monoclonal antibody that binds to HtrA1, wherein the antibody comprises the following six hypervariable regions (HVRs): an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 4;an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5;an HVR-H3 comprising the amino acid sequenc
1. An isolated monoclonal antibody that binds to HtrA1, wherein the antibody comprises the following six hypervariable regions (HVRs): an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 4;an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5;an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 6;an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 1;an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 2; andan HVR-L3 comprising the amino acid sequence of SEQ ID NO: 3. 2. The antibody of claim 1, comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7; or (c) a VH sequence as in (a) and a VL sequence as in (b). 3. The antibody of claim 2, comprising (a) a VH sequence of SEQ ID NO: 8; (b) a VL sequence of SEQ ID NO: 7; or (c) a VH sequence as in (a) and a VL sequence as in (b). 4. The antibody of claim 1, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 5. The antibody of claim 1, wherein the antibody is an antibody fragment that binds to HtrA1. 6. An immunoconjugate comprising the antibody of claim 1 and a cytotoxic agent. 7. A pharmaceutical formulation comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 8. An isolated monoclonal antibody that binds to HtrA1, wherein the antibody comprises the following six hypervariable regions (HVRs): an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20;an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5;an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 6;an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 1;an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 2; andan HVR-L3 comprising the amino acid sequence of SEQ ID NO: 3. 9. The antibody of claim 8, comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 29; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7; or (c) a VH sequence as in (a) and a VL sequence as in (b). 10. The antibody of claim 9, comprising (a) a VH sequence of SEQ ID NO: 29; (b) a VL sequence of SEQ ID NO: 7; or (c) a VH sequence as in (a) and a VL sequence as in (b). 11. The antibody of claim 8, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 12. The antibody of claim 8, wherein the antibody is an antibody fragment that binds to HtrA1. 13. An immunoconjugate comprising the antibody of claim 8 and a cytotoxic agent. 14. A pharmaceutical formulation comprising the antibody of claim 8 and a pharmaceutically acceptable carrier. 15. An isolated monoclonal antibody that binds to HtrA1, wherein the antibody comprises the following six hypervariable regions (HVRs): an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20;an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5;an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 6;an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 18;an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 2; andan HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19. 16. The antibody of claim 15, comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 29; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 28; or (c) a VH sequence as in (a) and a VL sequence as in (b). 17. The antibody of claim 16, comprising (a) a VH sequence of SEQ ID NO: 29; (b) a VL sequence of SEQ ID NO: 28; or (c) a VH sequence as in (a) and a VL sequence as in (b). 18. The antibody of claim 15, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 19. The antibody of claim 15, wherein the antibody is an antibody fragment that binds to HtrA1. 20. An immunoconjugate comprising the antibody of claim 15 and a cytotoxic agent. 21. A pharmaceutical formulation comprising the antibody of claim 15 and a pharmaceutically acceptable carrier. 22. An isolated monoclonal antibody that binds to HtrA1, wherein the antibody comprises the following six hypervariable regions (HVRs): an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20;an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5;an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 6;an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 21;an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 2; andan HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22. 23. The antibody of claim 22, comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 29; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 30; or (c) a VH sequence as in (a) and a VL sequence as in (b). 24. The antibody of claim 23, comprising (a) a VH sequence of SEQ ID NO: 29; (b) a VL sequence of SEQ ID NO: 30; or (c) a VH sequence as in (a) and a VL sequence as in (b). 25. The antibody of claim 22, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 26. The antibody of claim 22, wherein the antibody is an antibody fragment that binds to HtrA1. 27. An immunoconjugate comprising the antibody of claim 22 and a cytotoxic agent. 28. A pharmaceutical formulation comprising the antibody of claim 22 and a pharmaceutically acceptable carrier. 29. An isolated monoclonal antibody that binds to HtrA1, wherein the antibody comprises the amino acid sequences of any one of the following sets of six HRV-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 sequences, respectively: SEQ ID NOs: 20, 5, 6, 1, 2, and 34;SEQ ID NOs: 47, 5, 6, 1, 2, and 35;SEQ ID NOs: 20, 5, 6, 1, 2, and 36;SEQ ID NOs: 48, 5, 6, 1, 2, and 3;SEQ ID NOs: 47, 5, 6, 1, 2, and 37;SEQ ID NOs: 49, 5, 6, 1, 2, and 3;SEQ ID NOs: 20, 5, 6, 1, 2, and 38;SEQ ID NOs: 20, 5, 6, 1, 2, and 39;SEQ ID NOs: 20, 52, 6, 1, 2, and 40;SEQ ID NOs: 20, 5, 53, 1, 2, and 41;SEQ ID NOs: 20, 52, 6, 1, 2, and 3;SEQ ID NOs: 47, 5, 6, 1, 2, and 42;SEQ ID NOs: 20, 5, 6, 33, 2, and 43;SEQ ID NOs: 20, 5, 6, 1, 2, and 44;SEQ ID NOs: 20, 5, 53, 1, 2, and 3;SEQ ID NOs: 50, 5, 6, 1, 2, and 45;SEQ ID NOs: 51, 5, 6, 1, 2, and 3; orSEQ ID NOs: 20, 52, 6, 1, 2, and 46. 30. The antibody of claim 29, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 31. The antibody of claim 29, wherein the antibody is an antibody fragment that binds to HtrA1. 32. An immunoconjugate comprising the antibody of claim 29 and a cytotoxic agent. 33. A pharmaceutical formulation comprising the antibody of claim 29 and a pharmaceutically acceptable carrier.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.